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Background: A large number of patients have hypertension that is resistant to currently available pharmacologic therapy.
Electrical stimulation of the carotid sinus baroreflex system has been shown to produce significant chronic blood pressure
decreases in animals. The phase II Rheos Feasibility Trial was performed to assess the response of patients with
multidrug-resistant hypertension to such stimulation.
Methods: The system consists of an implantable pulse generator with bilateral perivascular carotid sinus leads. Implanta-
tion is performed bilaterally with patients under narcotic anesthesia (to preserve the reflex for assessment of optimal lead
placement). Dose-response testing at 0 to 6 V is assessed before discharge and at monthly intervals thereafter; the device
is activated after 1 month’s recovery time. This was a Food and Drug Administration–monitored phase II trial performed
at five centers in the United States.
Results: Ten patients with resistant hypertension (taking a median of six antihypertensive medications) underwent
implantation. All 10 were successful, with no significant morbidity. The mean procedure time was 198 minutes. There
were no adverse events attributable to the device. Predischarge dose-response testing revealed consistent (r  .88)
reductions in systolic blood pressure of 41 mm Hg (mean fall is from 180-139 mm Hg), with a peak response at 4.8 V
(P < .001) and without significant bradycardia or bothersome symptoms.
Conclusions: A surgically implantable device for electrical stimulation of the carotid baroreflex system can be placed safely and
produces a significant acute decrease in blood pressure without significant side effects. (J Vasc Surg 2006;44:1213-8.)Hypertension, defined as systolic blood pressure (SBP)
more than 140 mm Hg and/or diastolic blood pressure
(DBP) more than 90 mm Hg, affects 31% of adults in the
United States, a number approaching 65 million people.1,2
Treatment of hypertension is the second most common
reason for physician office visits and is the leading indica-
tion for prescribing medications to an adult.3 Effective
treatment reduces the incidence of stroke, myocardial in-
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Patients with blood pressures less than 130/80 mm Hg
experience a risk reduction for cardiac events twice that of
those with blood pressures of only 140/90 mm Hg, and
the risk of cardiovascular death has been shown to double
with each increment of 20/10 mmHg that blood pressure
exceeds 115/75 mm Hg.5
Unfortunately, only 25% to 34% of persons with hyper-
tension have their blood pressure controlled at a level of
140/90 mm Hg.5 It is estimated that failure to control
blood pressure is due to noncompliance with prescribed
medication in up to 50% of patients.6-11 In a large number
of patients, however, inadequate control may be due to
inadequate therapy and/or true resistance to maximal ap-
propriate antihypertensive therapy. It has been estimated
that 30% of hypertension cases cannot be controlled with
medications and can be considered resistant to treatment.12
Of these, a subset have truly dangerous hypertension that
places them at significant risk of virulent cardiovascular
disease.
Electrical stimulation of the carotid body has success-
fully decreased blood pressure in acute and chronic normo-
tensive and hypertensive13-18 animal models and acutely
during carotid endarterectomy in humans.19 On the basis
of this work, a device has been developed to electrically
activate the carotid baroreflex and decrease blood pressure
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findings and early European clinical trial results,20 the Food
and Drug Administration (FDA) approved a phase II fea-
sibility trial, which began in March 2005, to explore the
utility of the Rheos Baroreflex Hypertension Therapy Sys-
tem (CVRx, Maple Grove, Minn) to produce this effect in
humans. The trial consists of 12 months of therapy; this
article describes the details of surgical implantation and the
early postoperative results of this trial and device in humans
with resistant hypertension. The primary objectives are (1)
description of technique, (2) documentation of safety, and
(c) assessment of peri-implantation immediate hemody-
namic effectiveness.
METHODS
The Rheos Baroreflex Hypertension Therapy System
currently consists of a programmable pulse generator capa-
ble of delivering between 1 and 7.5 V in a temporally
variable pattern, along with two electrodes designed to be
placed at the carotid bulb. This requires surgical implanta-
tion by means of open carotid exposure, but the compo-
nents are then tunneled subcutaneously, in a fashion similar
to pacemaker placement (Fig 1).
This phase II trial was managed by the FDA, and all
protocols were approved by each implanting center’s insti-
tutional review board. All patients were under the care of
internists, nephrologists, or cardiologists specializing in the
treatment of hypertension, as well as a vascular surgeon
interested in this problem. Eligibility was limited to patients
with resistant hypertension, defined as SBP greater than
160 mm Hg despite receiving maximal appropriate doses of
three or more antihypertensive medications, including a
diuretic.5 Entrance criteria included maximization of anti-
hypertensive treatment, elimination of secondary causes of
hypertension (such as renal artery stenosis or adrenal tu-
mors) exclusion of baroreflex dysfunction (absence of dra-
matic postural pressure changes), and absence of carotid
disease (defined as a stenosis, if present, of 50% by duplex
ultrasonography and no prior surgery or neck radiation). It
is important to note that all patients had to be deemed
compliant with their antihypertensive therapy before con-
Fig 1. Illustration of the Rheos BaroreflexHypertension Therapy
System.sideration for enrollment (Tables I and II, online only).After informed consent and enrollment onto the study,
patients underwent 24-hour ambulatory blood pressure
monitoring. As described below, patients underwent bilat-
eral lead implantation by using appropriate anesthetic man-
agement and perioperative pharmacologic control of their
blood pressure. At the time of implantation, while the
patient was still under anesthesia and the wounds were
open, the blood pressure response to voltages between 1
and 6 V was determined (acute dose-response testing).
Dose-response testing was repeated before hospital dis-
charge (postoperative day 1 or 2). Patients will be followed
for 13 months after implantation, with all antihypertensive
medications continued for the first 4 months (unless mod-
ification is deemed necessary for patient safety).
Description of surgical procedure
On the day of surgery, aspirin and -blockers are admin-
istered. Typically, angiotensin-converting enzyme inhibitors
and angiotensin receptor– blocking agents are held, and other
antihypertensive agents are held at the discretion of the at-
tending surgeon (if needed, blood pressure can be acutely
controlled with sodium nitroprusside or nitroglycerin).
Proper anesthetic management is critical, because the
baroreceptor reflex is very easily blunted by many anesthet-
ics, including sevoflurane, nitrous oxide, isoflurane, and
halothane, and, to a lesser extent, intravenous agents such
as propofol.21-25 If blunting occurs, the optimal location
for the carotid sinus electrode may be very difficult to
identify.
From the perspective of anesthetic management, the
operation can be divided into three phases: phase 1, induc-
tion of anesthesia and exposure of the carotid bifurcations;
phase 2, carotid sinus mapping, electrode fixation, and
testing; and phase 3, tunneling and wound closure. In
general, inhalation anesthetics should be minimized or
avoided during the first two phases, but conventional anes-
thesia can be used during phase 3.
Phase 1: anesthetic induction and exposure of the
bifurcation. Initial induction and maintenance of anes-
thesia should primarily be performed with intravenous
agents. It is best to avoid sevoflurane, but agents such as
isoflurane, at low doses, have been used successfully if the
agent is discontinued with sufficient time to allow it to clear
from the patient before mapping and dose-response testing
are initiated. The carotid bifurcations may be exposed by
using oblique or vertical incisions at the discretion of the
surgeon; both sides of the neck, as well as the space for the
generator pocket, must be draped into the field. In general,
the bifurcation should be dissected en masse, with care
taken to avoid or minimize any dissection in the area of the
bifurcation and distally between the internal and external
carotid arteries to avoid trauma to the carotid sinus neuro-
vascular bundle.
Phase 2: carotid sinus mapping and electrode posi-
tioning. To identify proper lead positioning, the barore-
flex must be fully functional; baroreflex blunting can be
minimized by using a combination of short-acting barbitu-
rates and narcotics.26 After exposure of the carotid bifurca-
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lead is temporarily attached to the implantable pulse gen-
erator (IPG). The IPG is controlled by a computer-based
programming system that communicates with the IPG by
using a radiofrequency couple similar to that used for
programming cardiac pacemakers. During the mapping
procedure, testing is initiated at a low voltage, and the
blood pressure–lowering effect is determined (this is gen-
erally seen within 30 seconds). The electrode position is
adjusted, and testing is repeated to identify the area associ-
ated with the optimal hemodynamic response. When the
optimal location is identified (defined as the greatest blood
pressure drop for a given voltage), the electrode is sutured
in place at that location. This mapping procedure is then
repeated on the contralateral side with the other electrode.
After bilateral implantation, a formal dose-response test is
performed to assess the effect of full bilateral activation.
Therapy is initiated at 1 V and increased at 1-minute
intervals in 1-V increments until a maximal dose of 6 V or a
hemodynamic end point is reached (SBP 90 mm Hg,
mean arterial blood pressure 60 mm Hg, or heart rate
[HR] 50/min).
Phase 3: tunneling and completion of procedure. At
this point, preservation of baroreflex function is no longer
critical for the conduct of the operation, and conventional
anesthetic techniques can be used. A pocket is created in
the infraclavicular space for the IPG, in a fashion similar to
pacemaker and implantable cardiac defibrillator implanta-
tion (the right side has been used preferentially to avoid
confusion with the typical left-sided pacemaker placement).
Next, tunnels are created between the cervical incisions and
the pocket created for the IPG, and the leads from the
carotid sinus electrodes are brought to the IPG pocket.
Strain-relief loops are created in the cervical incisions, the
leads are connected to the IPG, and redundant lead length
is coiled in the IPG pocket deep to the IPG. Impedance is
tested to ensure the integrity of the electrical connections,
and the incisions are closed. After surgery, the patient’s
usual antihypertensive medical regimen is resumed.
Dose-response testing
Dose-response testing is performed before hospital dis-
charge. Blood pressure is measured by using a cuff appro-
priately sized for the patient; the same arm is always used.
Patients are tested in their hospital beds and remain still and
quiet until a stable blood pressure is obtained. Baroreflex
activation therapy is then initiated at 1 V and continued for
3 to 5 minutes, at which time blood pressure and HR are
recorded manually. Voltage is then increased, and vital
signs are recorded at the end of each activation period until
a final dose of 6 V is delivered or the patient reaches a
prospectively defined hemodynamic end point (SBP 100
mm Hg, mean arterial blood pressure 60 mm Hg,
and/or HR 50/min).
Analysis
Data used in this analysis were recorded on case report
forms and subsequently entered and stored by using con-ventional computerized spreadsheet methods. Maximal re-
sponse, determined for each patient, was compared with
the baseline value by using paired t testing. Repeated-
measures analysis of variance and regression analysis were
used to determine the significance of changes over time
during dose-response testing, and t testing and 2 analysis
were used, as appropriate, for comparing continuous and
categorical variables, respectively. Unless otherwise speci-
fied, data are expressed as mean  SD.
RESULTS
A total of 10 patients were enrolled in the US Rheos
Feasibility Trial, all experiencing resistant hypertension
while receiving optimal medical management.5 An addi-
tional 14 patients were screened; 11 did not meet enroll-
ment criteria, and 3 eligible patients declined participation.
Patient demographics are presented in Table III. At enroll-
ment, mean office cuff blood pressures were 175 22 mm
Hg SBP (range, 204-144 mm Hg) and 101  22 mm Hg
DBP (range, 142-70 mm Hg) despite an average of 6.2 
2.3 (range, 3-9) antihypertensive medications each. The
mean age was 50 years (range, 33-71 years), andmean body
mass index was 34.3 kg/m2 (range, 29-51 kg/m2). Six of
the patients were male, four were black, and six were white.
All patients underwent successful bilateral implanta-
tion. There were no unanticipated serious procedure- or
device-related adverse events or perioperative deaths. A
small number of patients reported subjective awareness of
muscle twitching, although no clinically visible effects were
seen, a phenomenon previously observed during early ex-
perience with this device. Procedure time averaged 198 
72 minutes (range, 109-345 minutes).
Intraoperative dose-response data are presented in
Table IV. The mean SBP decreased from 170 to 133 mm
Hg, a reduction of 37mmHg (range, 9-86mmHg), at 6 V
(P  .05). In a similar fashion, DBP decreased from 88 to
64 mmHg, a decrease of 24 mmHg (P .055), and pulse
pressure decreased from 81 to 68 mm Hg (P  .05). HR
also decreased from 71/min to 63/min (P  .05), and in
all cases, consistent dose-response curves were apparent.
The results of the first postimplantation “awake” dose-
Table III. Patient baseline demographic data (n  10)
Variable Data
Sex 4 female, 6 male
Race 4 black, 6 white
Age (y) 50  13 (33-71)
BMI (kg/m2) 34.3  6.7 (29-51)
Office cuff BP (mm Hg)
Systolic 175  22 (144-204)
Diastolic 101  22 (70-142)
Mean 24-h ambulatory BP (mm Hg)
Systolic 163  17 (110-222)
Diastolic 96  12 (60-135)
Mean No. antihypertensive medications 6.2  2.3 (3-9)
BMI, Body mass index; BP, blood pressure.
All data are expressed as mean  SD, with ranges following in parentheses.response test are shown in Table V and Fig 2. The mean
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mmHg (range, 22-104mmHg; P .001). It is interesting
to note that the maximum decrease was seen at an average
of 4.8 1.5 V (range, 2-6 V). DBP andHR again declined,
Table IV. Intraoperative dose-response curves
Variable 0 1
SBP (mm Hg) 170 158
Incremental decrease (mm Hg) 12
DBP (mm Hg) 88 83
PP (mm Hg) 81 75
HR (/min) 71 69
SBP, Systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate
Data are expressed as means, and curves were analyzed for significance by u
Table V. Predischarge dose-response curves
Variable 0 1
No. patients* 10 10
SBP (mm Hg) 180 163
Incremental decrease (mm Hg) 17
DBP (mm Hg) 81 76
PP (mm Hg) 98 87
HR (/min) 79 79
SBP, Systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate
Data are expressed as means, and curves were analyzed for significance by u
*Note that four patients reached hemodynamic end points (as defined in th
Fig 2. Predischarge dose-response curves (all patients, to 4 V
only). a, Systolic blood pressure. b, Heart rate.decreasing 19 mm Hg (range, 11-82 mm Hg; P  .005)and 9/min (range, 2/min to 25/min; P  .005), respec-
tively. The relationships between dose (voltage) and hemo-
dynamic response were highly linear, with r  0.88 for
voltage vs SBP and r  0.9 for voltage vs HR. The hemo-
dynamics of the five patients who achieved the full range of
therapy (ie, received the full 6 V without reaching a hemo-
dynamic end point) showed similar results, with relation-
ships between voltage and hemodynamic response also
highly linear (r  0.93 for HR and r  0.97 for SBP).
Mean follow-up as of May 2006 is 10 months (range,
4-14 months), and all patients have finished 4 months’
follow-up (3 months’ stimulation). Two generators have
had to be changed for planned battery replacement in
patients requiring high voltages for blood pressure control.
One infection has occurred in the US trial and one in
Europe; the worldwide total infection rate is 5.5% and is
expected to decrease with decreasing IPG size. The US
infection occurred after the 4-month follow-up visit and
was successfully treated by complete excision of the device,
with an uneventful recovery. This patient is being followed
up in the protocol but did not have another device im-
planted. No other long-term morbidity has occurred.
DISCUSSION
Perioperative results from the group of the first 10
patients enrolled in this FDA-approved phase II feasibility
trial demonstrate that the Rheos Baroreflex Hypertension
Therapy System can be safely implanted in patients with
severe hypertension and associated cardiovascular risk fac-
Dose (V)
P value3 4 5 6
144 137 136 133 .05
26 33 34 37
79 71 70 64 .055
65 66 66 68 .05
71 70 67 63 .05
ulse pressure.
epeated-measures analysis of variance.
Dose (V)
P value3 4 5 6
10 10 6 5
141 138 140 139 .001
39 42 40 41
60 63 60 62 .005
81 75 80 77 .005
73 72 75 70
ulse pressure.
epeated-measures analysis of variance.
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sive, with a mean SBP decrease of 37 mm Hg occurring
without troubling bradycardia at easily achievable voltages.
Predischarge dose-response tests in the awake state provide
similar results, showing a mean SBP reduction of 41 mm Hg
(achieved at a mean of 4.7 V), again without significant
bradycardia or perceptible side effects. In fact, because several
patients did not receive stimulation beyond 4 V, the maxi-
mal effect at 6 V might have been even greater if these
patients had been further stimulated. Hemodynamic re-
sponses correlate highly with applied voltage, thus suggest-
ing that designing strategies for more sophisticated inter-
vention in the future may well be straightforward.
The mechanism of baroreflex activation–induced blood
pressure reduction has been intensively investigated in both
normotensive and hypertensive (induced by obesity and the
infusion of angiotensin II) animals in a large body of work
by Thomas Lohmeier at the University of Mississippi. His
work has shown that baroreflex activation therapy produces
a global reduction in sympathetic nervous system activity,
as measured by a decrease in plasma norepinephrine levels
and HR. In addition, whereas a reduction in arterial pres-
sure approaching 20 mm Hg is typically associated with
activation of the renin-angiotensin system, comparable re-
ductions in blood pressure produced by electrical stimula-
tion of the baroreflex system in this fashion uniquely lead to
unaltered plasma renin levels during stimulation. In sum-
mary, work from this laboratory supports the hypothesis
that electrical baroreflex stimulation decreases blood pres-
sure by reducing sympathetic nervous system activity and
preventing activation of the renin-angiotensin-aldosterone
system.13-18,26-28
The effects of electrical stimulation of the carotid sinus
to treat hypertension were first evaluated in the late 1950s
in animals and humans with resistant hypertension. These
devices were bulky, lacked external dose control, and had
significant current leak from the electrodes, thus resulting
in extraneous muscle and nerve stimulation, although the
concept of an implantable pulse stimulator controlled via
external radiofrequency signals was described as early as
1965.29-33 In a report of eight patients treated, coinciden-
tally, at the University of Rochester, Schwartz et al34 de-
scribed a mean sustained reduction in SBP of 48 mm Hg;
six of the patients were able to discontinue blood pressure
medications altogether.
Interest in this phenomenon resurfaced in the past
decade or so, largely through Lohmeier’s animal investiga-
tions cited previously. In preparation for larger human
trials, Schmidli et al19 studied the acute response to barore-
flex activation therapy in patients undergoing elective ca-
rotid surgery. After exposure of the carotid sinus, an elec-
trode was placed on the carotid sinus, and the baroreflex
was activated. Despite the absence of carotid sinus mapping
or specialized anesthetic techniques, a mean SBP reduction
of 18 mm Hg was achieved. Results of chronic carotid sinus
stimulation were first reported in 2005 in a group of five
patients treated at University Hospital, Bern, Switzerland.
At 4 months’ follow-up, dose-response testing resulted in a20 to 40 mm Hg decrease in SBP, which seemed to be
stable to 4 months.20 As of May 2006, the Rheos Barore-
flex Hypertension Therapy System in its current version has
been implanted in 25 patients in Europe (Device-Based
Therapy in Hypertension Trial; DEBuT-HT). Finally, very
preliminary work in animals suggests that this therapy may
be of benefit in heart failure, as well.35,36
The current system addresses many of the challenges of
the earlier devices. Extraneous nerve and muscle stimula-
tion and pain resulting from current spread have been
largely solved by using modern electrode technologies. The
technique of placement of the electrode on the carotid
sinus reduces the possibility of damage to the carotid sinus
nerves and allows the use of established techniques com-
monly used in the treatment of atherosclerotic disease of
the carotid bifurcation for electrode implantation. This
facilitates electrode application, makes the operation easier,
and shortens the learning curve for the implant procedure.
Finally, advances in implantable medical devices allow the
system to reliably deliver stable and controlled therapy that
can be customized for each patient.
In summary, results in the first group of 10 patients
who received implants in the United States suggest that
chronic electrical stimulation of the carotid sinus can safely
be performed and can, in the short-term, produce signifi-
cant reductions in blood pressure: SBP reductions of 41
mm Hg were achieved at 4.8 V before discharge. These
data parallel emerging results from Europe, which, along
with theoretical and animal work, suggest that this effect is
durable, although follow-up is as yet extremely limited.
Further experience will be required before the role of this
therapy in the treatment of hypertension is known, but
these data suggest that a promising alternative approach
exists for the large group of patients with resistant hyper-
tension.
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Volume 44, Number 6 Illig et al 1218.e1Table I, online only. Rheos feasibility trial inclusion
criteria
21 y of age
Bilateral carotid bifurcations located below C3-4 (determined by
duplex ultrasonography)
Office cuff blood pressure 160 mm Hg despite at least 2 mo of
stable therapy on 3 antihypertensive medications, including a
diuretic (JNC-7* definition of resistant hypertension)
Certified by investigator as compliant to taking full doses of
medications
Reviewed by Screening/Adjudication Committee to meet study
entrance criteria
Have signed an approved informed consent for participation in
this study
*Seventh Report of the Joint National Committee on the Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure.5Table II, online only. Rheos feasibility trial exclusion
criteria




Carotid stenosis 50% (by ultrasonography or angiographic
evaluation)
Grade C ulcerative plaque (plaque with multiple cavities or a
cavernous appearance by ultrasonography or angiographic
evaluation)
Prior surgery or radiation in either carotid sinus region
Currently have implanted electrical medical device such as a
pacemaker, defibrillator, or neurologic stimulation
Pregnant or contemplating pregnancy during the 13-mo
follow-up period
Currently undergoing dialysis
Hypertension secondary to a treatable cause (for example, renal
artery stenosis or hormonally active tumor)
Clinically significant cardiac valvular disease (defined subjectively
by the enrolling cardiologist)
Unable to comply with protocol requirements
Unlikely to survive the protocol follow-up period
Enrolled in another concurrent clinical trial
